Impact of tofacitinib treatment on human B-cells in vitro and in vivo

详细信息    查看全文

• 作者：Marta Rizzi^a ; ^b ; ^{marta.rizzi@uniklinik-freiburg.de} ; Raquel Lorenzetti^a ; Kathleen Fischer^a ; Julian Staniek^a ; Iga Janowska^a ; Arianna Troilo^a ; Valentina Strohmeier^a ; Miriam Erlacher^c ; Mirjam Kunze^d ; Bettina Bannert^a ; ^e ; Diego Kyburz^e ; Reinhard E. Voll^a ; ^b ; Nils Venhoff^a ; Jens Thiel^a
• 关键词：B-lymphocytes ; Tofacitinib ; Immune modulation ; tsDMARDs ; JAK inhibitors ; Rheumatoid arthritis
• 刊名：Journal of Autoimmunity
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：77
• 期：Complete
• 页码：55-66
• 全文大小：2727 K
• 卷排序：77

文摘

B-cells are pivotal in pathogenesis of rheumatoid arthritis and are activated via common γ-chain cytokine receptors. Tofacitinib, a JAK inhibitor, inhibits plasmablast development and antibody secretion from naive B-cells. Treatment with tofacitinib may impair immune responses to new antigens. Vaccination against new antigens prior to tofacitinib treatment should be considered. Tofacitinib does not influence the proportion of B-cell subpopulations but their absolute numbers in vivo.